UPDATE 2-Revance Therapeutics' Botox rival succeeds in late-stage trial
December 04, 2018 at 11:12 AM EST
A potential rival for Allergan Plc's blockbuster Botox has passed a late-stage study, putting drug developer Revance Therapeutics Inc on course to file for U.S. marketing approval next year.
